Product Images Donepezil Hydrochloride

This appears to be a table showing ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale) changes from baseline in patients receiving either Donepezil Hydrochloride Tablets (at doses of 5 mg/day or 10 mg/day) or a Placebo, at 6, 12, and 18 weeks of drug treatment. The table also indicates the occurrence of clinical improvement or decline in patients.*

The document appears to be a graph or a chart showing the cumulative percentage of patients under the treatment of Donepezil Hydrochloride Tablets. The y-axis shows the percentage of patients (ranging from 0 to 100) while the x-axis shows the change in ADAS-cog (ranging from -15 to 15). The graph includes three categories: 10 mg/day Donepezil Hydrochloride Tablets, 5 mg/day Donepezil Hydrochloride Tablets, and placebo. The categories are further divided into four columns showing the percentage of patients having no change, 4 points, 7 points, and more.*

This text displays a chart showing the ADAS-cog change from baseline over weeks of drug treatment with Donepezil hydrochloride tablets 10mg/day, Donepezil hydrochloride tablets 5mg/day, and a placebo. It also indicates clinical improvement or decline.*

This is a table that shows the cumulative percentage of patients who have had a change in their ADAS-COG score after taking Donepezil Hydrochloride Tablets at different doses of 5mg/day and 10mg/day, as well as a placebo group. The changes are categorized by treatment groups, with either 7, 4 or 0 points, and indicate whether there was improvement, no change, or a decline in cognitive function. The table also shows the change from baseline in ADAS-COG scores over a period of 15 weeks.*

The text describes a chart or graph that shows the cumulative percentage of patients. The chart or graph appears to compare the effects of Donepezil Hydrochloride Tablets (10 mg/day) with the effects of a placebo. The chart or graph also includes data on SIB Change from Baseline.*

This is a figure showing the change in ADCS-ADL-Severe score over 6 months of treatment for patients taking Donepezil Hydrochloride Tablets 10 mg/day versus those on placebo. The x-axis represents the months of drug treatment and the y-axis represents the change from baseline in the ADCS-ADL-Severe score. The plot shows that patients on Donepezil had a greater clinical improvement compared to those on placebo, as indicated by the positive change from baseline in their score. Those on placebo experienced a decline in their score.*

This is a graph indicating the Cumulative Percentage of Patients, comparing the effectiveness of Donepezil Hydrochloride Tablets and Placebo, based on the ADCS-ADL Change from Baseline. The x-axis shows the percentage values, while the y-axis lists Donepezil Hydrochloride Tablets and Placebo.*

This is a description of a medication containing 5mg of Donepezil Hydrochloride. The tablets are coated with a film and are meant to be stored between 68-77°F. The proper dosage is not provided in the text, but can be found on the accompanying prescription information. The medication should be dispensed in a moisture-resistant container with an airtight closure. The text also contains information about the manufacturer and the product code.*

Each film-coated tablet contains 10mg donepezil hydrochloride, USP. It should be stored at 20° to 25°C (68° to 77°F) with excursions permitted at 15° to 30°C (59° to 86°F). The tablets need to be dispensed in a tight, light-resistant container with a child-resistant closure. The usual dosage should be followed carefully, and the prescribing information should be consulted. This product is made by Torrent Pharmaceuticals LTD and comes in a pack of 30 tablets. The details for dispensing the medication are provided in the accompanying patient's information sheet. This product is available only by prescription.*